2N1E
| MAX1 peptide fibril | Descriptor: | MAX1 peptide | Authors: | Nagy-Smith, K, Moore, E, Schneider, J, Tycko, R. | Deposit date: | 2015-03-30 | Release date: | 2015-07-29 | Last modified: | 2023-06-14 | Method: | SOLID-STATE NMR | Cite: | Molecular structure of monomorphic peptide fibrils within a kinetically trapped hydrogel network. Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
4FOD
| Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 36 | Descriptor: | 4-fluoro-N-{(2E)-6-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-1-[cis-4-(propan-2-ylcarbamoyl)cyclohexyl]-1,3-dihydro-2H-benzimidazol-2-ylidene}benzamide, ALK tyrosine kinase receptor, GLYCEROL | Authors: | Whittington, D.A, Epstein, L.F, Chen, H. | Deposit date: | 2012-06-20 | Release date: | 2012-07-11 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer. J.Med.Chem., 55, 2012
|
|
4FOC
| Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 2 | Descriptor: | ALK tyrosine kinase receptor, methyl cis-4-[2-(benzoylamino)-6-(piperidin-1-ylmethyl)-1H-benzimidazol-1-yl]cyclohexanecarboxylate | Authors: | Whittington, D.A, Epstein, L.F, Chen, H. | Deposit date: | 2012-06-20 | Release date: | 2012-07-11 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer. J.Med.Chem., 55, 2012
|
|
4FOB
| Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 1 | Descriptor: | ALK tyrosine kinase receptor, N-{1-[cis-4-(hydroxymethyl)cyclohexyl]-5-(piperidin-1-ylmethyl)-1H-benzimidazol-2-yl}-3-(prop-2-en-1-ylsulfamoyl)benzamide | Authors: | Whittington, D.A, Epstein, L.F, Chen, H. | Deposit date: | 2012-06-20 | Release date: | 2012-07-11 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer. J.Med.Chem., 55, 2012
|
|
1ZIG
| GAGA RNA TETRALOOP, NMR, 10 STRUCTURES | Descriptor: | RNA (5'-R(*GP*GP*GP*CP*GP*AP*GP*AP*GP*CP*CP*U)-3') | Authors: | Jucker, F.M, Heus, H.A, Yip, P.F, Moors, E, Pardi, A. | Deposit date: | 1996-07-27 | Release date: | 1997-03-12 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | A network of heterogeneous hydrogen bonds in GNRA tetraloops. J.Mol.Biol., 264, 1996
|
|
1ZIH
| GCAA RNA TETRALOOP, NMR, 10 STRUCTURES | Descriptor: | RNA (5'-R(*GP*GP*GP*CP*GP*CP*AP*AP*GP*CP*CP*U)-3') | Authors: | Jucker, F.M, Heus, H.A, Yip, P.F, Moors, E, Pardi, A. | Deposit date: | 1996-07-27 | Release date: | 1997-03-12 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | A network of heterogeneous hydrogen bonds in GNRA tetraloops. J.Mol.Biol., 264, 1996
|
|
1ZIF
| GAAA RNA TETRALOOP, NMR, 10 STRUCTURES | Descriptor: | RNA (5'-R(*GP*GP*GP*CP*GP*AP*AP*AP*GP*CP*CP*U)-3') | Authors: | Jucker, F.M, Heus, H.A, Yip, P.F, Moors, E, Pardi, A. | Deposit date: | 1996-07-27 | Release date: | 1997-03-12 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | A network of heterogeneous hydrogen bonds in GNRA tetraloops. J.Mol.Biol., 264, 1996
|
|